Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy for the Treatment of Indian Kala-Azar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of active VL with consistent signs and symptoms (e.g., fever, splenomegaly).~* Confirmed diagnosis by bone-marrow or splenic aspirate smear showing characteristic amastigotes.~* Male or female.~* Ages 12 to 65 years.~* Both newly diagnosed cases and patients who have received previous treatment (in the latter case a 2-week wash-out will be required before starting the study treatment).~* WBC \> 1,000/mm3.~* Hemoglobin ≥ 4 g/dL~Exclusion Criteria:~* Pregnancy or breast-feeding.~* HIV positive serology.~* ASAT, ALAT, AP ≥ 3 times upper limit of normal range.~* Bilirubin ≥ 2 times upper limit of normal range.~* Prothrombin time ≥ 5 seconds above control.~* Serum creatinine or BUN ≥ 1.5 times upper limit of normal range.~* Any medical condition or situation that compromises compliance with study procedures.~* HIV

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).